Xlife Sciences AG: Transaction with Baliopharm AG
Xlife Sciences AG has reached a licensing agreement with the biotech firm Baliopharm AG, located in Basel. According to the agreement, Xlife Sciences AG will receive 10% of future income from license fees of Baliopharm AG. The Basel-based company is a leader in innovative antibody therapies for the treatment of acute and chronic inflammatory diseases.
According to the concluded licensing agreement with Baliopharm AG, Xlife Sciences AG will receive 10% of all future licensing income up to a maximum of 300 million euros. This applies to the company's entire line of active ingredients. Xlife Sciences AG thus participates directly in the future success and innovative strength of a leading biotech company in the field of antibody therapies with this transaction.
On the 18th of December, Baliopharm AG received the approval to start Phase I of medical drug Atrosimab for the treatment of Non-Alcoholic SteatoHepatitis (NASH) by the Australian Healthcare Administration. NASH is the most frequent chronic liver disease. The Global Liver Institute estimates that there are more than 115 million people affected globally by NASH. According to the Institute, this number could double by 2030. In Germany, 1.5 to 2 million patients have at least a mild form of NASH. Under more severe circumstances, the disease can lead to irreversible liver damage (liver cirrhosis) and cannot be treated therapeutically. In this way, Baliopharm AG views this as a huge market.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
Xlife Sciences AG
0041 44 385 84 60
Regulated Unofficial Market in Frankfurt, Munich
EQS News ID:
For media inquiries
Oliver R. Baumann
CEO Xlife Sciences AG
Tel. +41 44 385 84 60
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AttackIQ Appoints New General Manager and Vice President of EMEA and APJ Regions13.4.2021 09:00:00 CEST | Press release
AttackIQ®, the leading independent vendor of Breach and Attack Simulation (BAS) systems, today announced that Ross Brewer has been promoted to General Manager and Vice President of Europe, Middle East and Africa (EMEA) and Asia Pacific Japan (APJ) regions. In his new role, Brewer will be responsible for developing the strategy to expand AttackIQ’s presence in the regions, including delivering IT security and risk management leaders with solutions to identify gaps in their security posture more effectively and prioritize security initiatives more efficiently. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005210/en/ Ross Brewer, General Manager and Vice President of Europe, Middle East and Africa (EMEA) and Asia Pacific Japan (APJ) regions. (Photo: Business Wire) Brewer brings more than 35 years of sales and management experience with technology organizations across the globe. He previously served as strategic advisor f
ADVA showcases 400ZR DCI solution with Acacia and Inphi13.4.2021 09:00:00 CEST | Press release
ADVA (FSE: ADV) today announced that it has successfully demonstrated interoperability between its next-generation FSP 3000 DCI open line system (OLS) and QSFP-DD 400ZR modules from Acacia Communications and Inphi Corporation. Conducted over a 120km amplified link, the tests show a clear path to commercial deployments of a complete solution with all the benefits of open, programmable networking. The trial featured 400Gbit/s WDM transport using low-power 400ZR pluggable QSFP-DD transceivers from Acacia and Inphi with ADVA’s FSP 3000 DCI OLS. It was carried out under real-world conditions with 400Gbit/s channels placed next to the test channels as well as a fully loaded spectrum. To validate three-way line-side interoperability, 400ZR was transmitted from Acacia to Inphi and vice versa. Test results showed that this multi-vendor ecosystem exceeds all OIF 400ZR Implementation Agreement performance metrics. Large-scale DCI network operators now have an easy and cost-effective route to a dy
BlueShore Financial Expands Relationship with Temenos to Further its Digital Transformation13.4.2021 09:00:00 CEST | Press release
Temenos (SIX: TEMN), the banking software company, today announced that BlueShore Financial, a boutique full service financial institution, is digitally transforming with Temenos. Powered by Temenos Infinity, the market-leading omnichannel digital banking product, BlueShore will extend its ‘HighTech-HighTouch’ experience to clients by leveraging explainable artificial intelligence (XAI). BlueShore will replicate the in-branch experience of its Financial Spa™ Branch designed around client-centered amenities, personalized service and expert advice, across all channels and devices, from onboarding to servicing through to retention. BlueShore clients are largely technologically and financially literate, but are time-starved and have complex financial needs. As such, BlueShore is focused on delivering expert advice and a premium, personalized client experience, both in-person and virtually, via the channel of their clients’ choice. In November 2020, as part of its initiative to build human
Acer, AMD, Arm, Intel, Micron, NXP, Qualcomm and Supermicro Confirm Participation in COMPUTEX 2021 Hybrid13.4.2021 08:52:00 CEST | Press release
The Taiwan External Trade Development Council (TAITRA) announced today that top global ICT companies Acer, AMD, Arm, Intel, Micron, NXP, Qualcomm and Supermicro will participate in the Online-Merge-Offline (OMO) exhibition “COMPUTEX 2021 Hybrid” from May 31 to June 30. This year, the OMO hybrid exhibition combines the onsite events with #COMPUTEXVirtual for an accessible experience that breaks time and geographical limitations by connecting IT ecosystems worldwide. Participants will have access to the latest industry trends through the platform, no matter where they are. Major tech companies committed to join COMPUTEX 2021 Hybrid, driving future innovations Tech giants have expressed their support for participating in COMPUTEX 2021 Hybrid, showing Taiwan is a leading player to restructure the high-end international technology supply chain. The global tech pioneers have developed deep confidence in the ecosystem built by COMPUTEX and are ready to seize opportunities to make groundbreaki
eShopWorld Appoints Martim Avillez Oliveira as Chief Commercial Officer - EMEA and APAC13.4.2021 08:01:00 CEST | Press release
eShopWorld (ESW), the leading cross-border ecommerce technology and services provider, today announces the appointment of Martim Avillez Oliveira as Chief Commercial Officer, EMEA and APAC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005546/en/ eShopWorld appoints Martim Avillez Oliveira as Chief Commercial Officer - EMEA and APAC (Photo: Business Wire) Oliveira is a former Executive Vice President at global supply chain and logistics specialist, Li & Fung, has 15 years of industry experience in retail and global sourcing, having worked with the world’s leading fashion brands and retailers, including Inditex, Marks & Spencer, J.Crew and Galeria Karstadt Kaufhof, managing end-to-end supply chains. In his new role, Oliveira will drive forward ESW’s strategic growth and development with a focus on crafting routes to market within and between the EMEA and APAC that enable retailers and brands to meet the huge latent dem
EpiEndo Pharmaceuticals Announces Launch of First-in-Human Clinical Trial of a Non-Antibiotic Macrolide for the Treatment of Chronic Inflammatory Airway Diseases13.4.2021 08:00:00 CEST | Press release
EpiEndo Pharmaceuticals (www.epiendo.com), a clinical-stage biopharmaceutical company developing novel non-antibiotic macrolide therapeutics for the treatment of inflammatory disorders, announced today that the first subjects have been dosed in the Company's first-in-human phase I clinical trial of its lead candidate, EP395, at the Medicines Evaluation Unit (MEU) in Manchester, UK (clinicaltrials.gov identification number NCT04819854). The trial is led by Professor Dave Singh, Professor of Respiratory Pharmacology at the University of Manchester and Medical Director at MEU. “I am delighted to say that our single ascending dose study has started and that the first six healthy subjects have been given a dose of EP395,” commented Dr. Ginny Norris, EpiEndo’s Chief Medical Officer. “The study will now continue with further single dosing and, later, multiple dosing. Dosing of our first subjects with EP395 is an important milestone for EpiEndo, as it brings us one step closer to offering a po
BIOCORP and ROCHE DIABETES CARE FRANCE Launch Mallya, an Innovative Medical Device to Better the Daily Life of Patients With Diabetes13.4.2021 08:00:00 CEST | Press release
Regulatory News: BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME) , a French company specialized in the design, development and manufacturing of innovative medical devices, and Roche Diabetes Care France, a reference company in the support of patients with diabetes, announce the launch in France of Mallya, a medical device available in pharmacies. Developed by BIOCORP, this smart insulin pen device collects and transfers insulin data with near 100% accuracy2. Rechargeable via its USB port, Mallya is compatible with most disposable insulin pens1. This innovation aims to simplify the daily life of patients with diabetes undergoing insulin therapy, and could help avoid errors or oversights. Healthcare companies BIOCORP and Roche Diabetes Care France are finalizing their collaboration - announced last June - with the distribution of Mallya smart devices for insulin injection pens since the beginning of April. Manufactured in Clermont-Ferrand (France), this innovation for pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom